Science 37 (NASDAQ:SNCE – Get Rating) is one of 41 publicly traded companies in the Commercial Physical Research industry, but how does it compare to its competitors? We will compare Science 37 to similar businesses based on the strength of valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
This table compares Science 37 and its competitors’ net margins, return on equity and return on assets.
|Net margins||Return on capital||Return on assets|
|Science 37 Competitors||-239.39%||-12.42%||-6.15%|
Risk and volatility
Science 37 has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Science 37’s competitors have a beta of 5.70, indicating that their average stock price is 470 % more volatile than the S&P 500.
Rating and earnings
This table compares Science 37’s revenue, earnings per share (EPS) and valuation to its competitors.
|Gross income||Net income||Price/earnings ratio|
|Science 37||$59.60 million||-$94.33 million||-0.48|
|Science 37 Competitors||$2.69 billion||$93.58 million||9.51|
Science 37’s competitors have higher revenue and earnings than Science 37. Science 37 trades at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and internal ownership
46.1% of Science 37 shares are owned by institutional investors. Comparatively, 59.9% of shares of all Commercial Physical Research companies are owned by institutional investors. 4.4% of Science 37 shares are owned by insiders. Comparatively, 11.5% of shares of all Commercial Physical Research companies are owned by insiders. Strong institutional ownership is an indication that major money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Science 37 and its rivals, as reported by MarketBeat.
|Estimates for sale||Hold the ratings||Buy ratings||Strong buy ratings||Rating score|
|Science 37 Competitors||41||606||1208||23||2.65|
Science 37 currently has a consensus target price of $10.00, suggesting a potential upside of 495.24%. As a group, “Commercial Physical Research” companies have a potential upside of 31.53%. Given Science 37’s stronger consensus rating and higher probable upside, analysts plainly believe Science 37 is more favorable than its peers.
Science 37’s rivals beat Science 37 on 9 of the 13 factors compared.
Science 37 Company profile
Science 37 Holdings, Inc. provides technology-based solutions that enable flexible clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including patients and researchers, nurses, coordinators and sponsors to power workflows, centralize evidence generation and harmonize data. Its platform also provides dedicated networks of patient communities, telemedicine researchers, mobile nurses, remote coordinators and connected devices to orchestrate flexible clinical trials; and broad configuration to support virtually every phase of the clinical trial and every indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Get Science 37 news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Science 37 and related companies with MarketBeat.com’s FREE daily email newsletter.